Literature DB >> 30284156

Reduction in Cannabis Use and Functional Status in Physical Health, Mental Health, and Cognition.

Larissa J Mooney1,2, Yuhui Zhu3, Caroline Yoo3, Jonathan Valdez3, Kevin Moino3, Jung-Yu Liao4, Yih-Ing Hser3.   

Abstract

Treatment for substance use disorders has traditionally been abstinence-oriented, but evaluating the merits of low-level cannabis use as potential treatment endpoint may identify benefits that are clinically relevant for treatment-seeking individuals who do not attain abstinence. This study explores if reduction in cannabis use to a lower level of use is related to improved physical health, mental health, and perceived cognitive functions. Study participants with a history of problematic cannabis use (n = 111) completed assessments. Regression models were used to explore the relationship between past 30-day cannabis use levels (abstinent [57%], low use [22%] defined as less than or equal to 3 days per week, and heavy use [22%] defined as 4 or more days of use per week) and functional status in physical health, mental health, and cognition. Compared to heavy users, both abstinent and low-use individuals were similarly associated with better global health, appetite, and depression outcomes. Abstinent users also reported improved sleep, anxiety, and self-reported cognitive functioning relative to heavy users. Thus, reduction in cannabis use to lower levels is associated with beneficial outcomes important to health and other areas of functioning in individuals with problematic cannabis use.

Entities:  

Keywords:  Cannabis use; Cognition; Functional outcomes; Health; Mental health

Mesh:

Year:  2018        PMID: 30284156      PMCID: PMC6293461          DOI: 10.1007/s11481-018-9813-6

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  22 in total

1.  Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis.

Authors:  Amy M Schreiner; Michael E Dunn
Journal:  Exp Clin Psychopharmacol       Date:  2012-06-25       Impact factor: 3.157

2.  Body mass index and marijuana use.

Authors:  Matthew Warren; Kimberly Frost-Pineda; Mark Gold
Journal:  J Addict Dis       Date:  2005

3.  Posttreatment Low-Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders: A 9-Year Follow-Up.

Authors:  Andrea H Kline-Simon; Raye Z Litten; Constance M Weisner; Daniel E Falk
Journal:  Alcohol Clin Exp Res       Date:  2017-02-07       Impact factor: 3.455

Review 4.  How important are sex differences in cannabinoid action?

Authors:  Liana Fattore; Walter Fratta
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life.

Authors:  Yih-Ing Hser; Larissa J Mooney; David Huang; Yuhui Zhu; Rachel L Tomko; Erin McClure; Chih-Ping Chou; Kevin M Gray
Journal:  J Subst Abuse Treat       Date:  2017-07-29

6.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

7.  Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments.

Authors:  Daniel J Buysse; Lan Yu; Douglas E Moul; Anne Germain; Angela Stover; Nathan E Dodds; Kelly L Johnston; Melissa A Shablesky-Cade; Paul A Pilkonis
Journal:  Sleep       Date:  2010-06       Impact factor: 5.849

Review 8.  Marijuana: respiratory tract effects.

Authors:  Kelly P Owen; Mark E Sutter; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

9.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

10.  The time course and significance of cannabis withdrawal.

Authors:  Alan J Budney; Brent A Moore; Ryan G Vandrey; John R Hughes
Journal:  J Abnorm Psychol       Date:  2003-08
View more
  7 in total

1.  Editors' Commentary for Special Issue: The 2017 CALDAR Summer Institute and International Conference Promoting Global Health-Precision Research in Substance Abuse, HIV, and Care.

Authors:  Linda Chang; Ming D Li; Yih-Ing Hser
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-31       Impact factor: 4.147

2.  Measuring Within-Individual Cannabis Reduction in Clinical Trials: A Review of the Methodological Challenges.

Authors:  Rachel L Tomko; Kevin M Gray; Marilyn A Huestis; Lindsay M Squeglia; Nathaniel L Baker; Erin A McClure
Journal:  Curr Addict Rep       Date:  2019-11-19

Review 3.  Adverse Effects of Recreational and Medical Cannabis.

Authors:  Ivan Urits; Karina Charipova; Kyle Gress; Nathan Li; Amnon A Berger; Elyse M Cornett; Hisham Kassem; Anh L Ngo; Alan D Kaye; Omar Viswanath
Journal:  Psychopharmacol Bull       Date:  2021-01-12

Review 4.  Down and High: Reflections Regarding Depression and Cannabis.

Authors:  Catherine Langlois; Stéphane Potvin; Atul Khullar; Smadar Valérie Tourjman
Journal:  Front Psychiatry       Date:  2021-05-14       Impact factor: 4.157

5.  A "Good" Smoke? The Off-Label Use of Cannabidiol to Reduce Cannabis Use.

Authors:  Davide Fortin; Vincent Di Beo; Sophie Massin; Yann Bisiou; Patrizia Carrieri; Tangui Barré
Journal:  Front Psychiatry       Date:  2022-03-17       Impact factor: 4.157

6.  Medical Students' Attitudes, Knowledge, and Beliefs about Medical Cannabis: A Qualitative Descriptive Study.

Authors:  Robin J Jacobs; Jessica Colon; Michael N Kane
Journal:  Cureus       Date:  2022-08-24

7.  Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder.

Authors:  Brian J Sherman; Michael J Sofis; Jacob T Borodovsky; Kevin M Gray; Aimee L McRae-Clark; Alan J Budney
Journal:  Psychol Addict Behav       Date:  2021-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.